Loading clinical trials...
Loading clinical trials...
An Open-Label, Multicenter, First-in-Human, Dose-Escalation and Expansion Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of DXC014 for Injection in Patients With Advanced Solid Tumors.
Conditions
Interventions
DXC014
Locations
3
China
Peking University First Hospital
Beijing, Beijing Municipality, China
Hunan Cancer Hospital
Changsha, Hunan, China
Zhejiang Cancer Hospital
Hangzhou, Zhejiang, China
Start Date
March 3, 2026
Primary Completion Date
October 20, 2030
Completion Date
October 20, 2030
Last Updated
April 24, 2026
NCT06043817
NCT05671510
NCT06844383
NCT06594926
NCT06487507
NCT05919264
Lead Sponsor
Hangzhou DAC Biotechnology Co., Ltd.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions